---
title: "Oklo's cancer-isotope plant lands with no buyer, no price and a $6.5 billion bill"
description: "Oklo, an advanced nuclear developer whose Aurora power plants have yet to sell a watt, won a Department of Energy selection to advance Groves 2 Forge, a Texas pilot plant for the cancer-treatment isotope lutetium-177. It is the company's first shot at revenue before its reactors, and the release sets no terms; the money behind the broader build-out is still equity, sold at the market."
publisher: "The Inference"
section: "Energy"
published: 2026-10-13T23:13:02.943Z
modified: 2026-10-13T23:13:02.943Z
canonical: https://theinference.org/article/oklo-s-cancer-isotope-plant-lands-with-no-buyer-no-price-and-a-6-5-billion-bill
language: en
keywords: "Oklo, Nuclear, Isotopes, Department Of Energy, Funding"
---

# Oklo's cancer-isotope plant lands with no buyer, no price and a $6.5 billion bill

> Oklo, an advanced nuclear developer whose Aurora power plants have yet to sell a watt, won a Department of Energy selection to advance Groves 2 Forge, a Texas pilot plant for the cancer-treatment isotope lutetium-177. It is the company's first shot at revenue before its reactors, and the release sets no terms; the money behind the broader build-out is still equity, sold at the market.

## The announcement sets no commercial terms

[Oklo](https://theinference.org/markets/companies/oklo), an advanced nuclear developer whose Aurora power plants have never sold a watt of electricity, said on October 13 that the Department of Energy's National Reactor Innovation Center [picked 12 developers across 13 projects for its Nuclear Energy Launch Pad](https://www.stocktitan.net/news/OKLO/oklo-to-advance-groves-2-forge-as-part-of-u-s-department-of-energy-s-ferd9b77bgl7.html), and that [Oklo](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001849056)'s Groves 2 Forge is among them [1]. Groves 2 Forge is a planned Texas pilot facility to produce, process and purify lutetium-177, an isotope that carries radiation directly to cancer cells [1]. The announcement names no contract value, no customer, no production volume and no federal dollar amount, and it says commercial-scale output requires Nuclear Regulatory Commission licenses Oklo does not yet hold [1].

## The market has already voted

Shares closed at $34.57 on October 8, 80 percent below the highest close of the prior year, at an enterprise value of $3.97 billion, down 75 percent from $15.95 billion in September 2025 [2][3]. Behind that price sits a bill. Consensus has Oklo burning cash every year through 2030, from about $520 million in 2026 to about $2.7 billion in 2030, which leaves roughly $6.5 billion of funding needs after the $192 million consumed in the first half of 2026 [2][3]. That is more than twice the $3.0 billion of cash and marketable securities reported at June 30 [2][3].

*Chart: **The bill left on Oklo's desk is twice its bank balance** Bars comparing Oklo's $3.0 billion of cash and marketable securities at June 30, its $3.97 billion enterprise value on October 8, and its roughly $6.5 billion consensus funding need for 2026 through 2030.*

*Cash and marketable securities at June 30, 2026; enterprise value on October 8, 2026; consensus free-cash-flow shortfall for 2026 through 2030 net of the $192 million first-half 2026 burn, an estimate. Sources: TIKR; Foreign Policy Journal. [2][3]*

*Chart: **Oklo's quarterly cash burn has quadrupled in five quarters** Column chart of Oklo's quarterly free cash flow from the first quarter of 2025 through the second quarter of 2026, deepening from a $19 million outflow to a $142 million outflow.*

*Quarterly free cash flow from Oklo's SEC filings, in billions of dollars. The quarterly outflow roughly tripled from the first quarter of 2026 to the second, reaching $142 million. Source: [9] Oklo, quarterly figures from its SEC filings. [9]*

## The first isotope revenue points to a different facility

Even the near-term isotope money points away from Groves 2 Forge. Management said on its August earnings call that first isotope revenue is more likely in the first part of 2027, from the Idaho Radiochemistry Laboratory, a facility already licensed by the Nuclear Regulatory Commission, while the Groves test reactor works up toward research quantities [4]. Oklo's first revenue in company history, about $1.2 million in the quarter ended in June, came mostly from services, not power or isotopes [4]. The funding route stays equity: about $1.9 billion was raised through at-the-market share sales in the first half, and [a fresh $1 billion program was signed on September 11](https://www.theglobeandmail.com/investing/markets/stocks/OKLO/pressreleases/4572540/oklo-launches-1-billion-at-the-market-stock-offering/) [5][6].

## The demand for lutetium-177 is real

Novartis's lutetium-177 prostate-cancer drug [Pluvicto sold $651 million in the second quarter](https://www.ad-hoc-news.de/boerse/news/corporate-news/novartis-stock-holds-firm-as-pluvicto-grows-43-percent-in-q2/69991532), up 43 percent in constant currencies, and many critical isotopes still come from aging or foreign facilities [7][1]. Suppliers are spending to close that gap: the isotope producer NorthStar Medical Technologies just secured up to $185 million from Hercules Capital to expand production and contract manufacturing [8]. Groves reached criticality in under a year, the first Reactor Pilot Program project on private land to do so [1]. On the power side, [Meta](https://theinference.org/markets/companies/meta) Platforms has agreed to support up to 1.2 gigawatts of reactor development in Ohio, prepaying to help fund fuel, and the data-center operator Equinix has paid an advance; neither amount is disclosed [4][2].

## What November decides

The third-quarter report, expected in November, is the first place isotope terms could appear [2][3]. Also open is a definitive agreement with Centrus Energy, the enriched-uranium supplier named in a [letter of intent to fuel up to five Aurora powerhouses](https://pulse2.com/oklo-centrus-deal-could-supply-haleu-for-five-aurora-powerhouses-as-fuel-fabrication-startup-activities-target-2027/) with deliveries starting in 2029; whether Oklo or its customers pay the fuel prepayments is unresolved [3][5]. Until a lutetium-177 buyer and a price appear, the isotope line changes nothing about who pays for the reactor build-out.

## Takeaway

The DOE selection gives Oklo a showcase, not revenue: the lutetium-177 pilot has no buyer or price, first isotope sales point to the Idaho lab in 2027, and a $6.5 billion consensus funding bill through 2030 still rests on selling stock.

## Sources

1. [StockTitan (Business Wire), Oklo to Advance Groves 2 Forge as Part of U.S. Department of Energy's Nuclear Energy Launch Pad Selection, 13 October 2026](https://www.stocktitan.net/news/OKLO/oklo-to-advance-groves-2-forge-as-part-of-u-s-department-of-energy-s-ferd9b77bgl7.html)
2. [TIKR, Oklo Stock Hit a 52-Week Low on October 8. Here's Why the Market Values Its Business at Just $4 Billion, 9 October 2026](https://www.tikr.com/blog/oklo-stock-hit-a-52-week-low-on-october-8-heres-why-the-market-values-its-business-at-just-4-billion)
3. [Foreign Policy Journal, Oklo (NYSE: OKLO) Stock Trades Near 52-Week Lows As Market Questions $4 Billion Valuation Against A $6.5 Billion Funding Gap, 10 October 2026](https://www.foreignpolicyjournal.com/2026/10/10/oklo-nyse-oklo-stock-trades-near-52-week-lows-as-market-questions-4-billion-valuation-against-a-6-5-billion-funding-gap/)
4. [The Motley Fool via MSN, Prediction: Oklo won't book its first commercial power revenue before 2028, 23 August 2026](https://www.msn.com/en-us/money/companies/prediction-oklo-won-t-book-its-first-commercial-power-revenue-before-2028/ar-AA2aLXgA)
5. [Pulse 2.0, Oklo: Centrus Deal Could Supply HALEU For Five Aurora Powerhouses As Fuel Fabrication Startup Activities Target 2027, 17 August 2026](https://pulse2.com/oklo-centrus-deal-could-supply-haleu-for-five-aurora-powerhouses-as-fuel-fabrication-startup-activities-target-2027/)
6. [The Globe and Mail (TipRanks), Oklo Launches $1 Billion At-The-Market Stock Offering, 12 September 2026](https://www.theglobeandmail.com/investing/markets/stocks/OKLO/pressreleases/4572540/oklo-launches-1-billion-at-the-market-stock-offering/)
7. [ad-hoc-news, Novartis stock holds firm as Pluvicto grows 43% in Q2, 24 August 2026](https://www.ad-hoc-news.de/boerse/news/corporate-news/novartis-stock-holds-firm-as-pluvicto-grows-43-percent-in-q2/69991532)
8. [Fierce Pharma, NorthStar locks down $185M as radiopharmaceutical isotope, CDMO expansion plans advance, 30 September 2026](https://www.fiercepharma.com/manufacturing/northstar-locks-down-180m-radiopharmaceutical-isotope-cdmo-expansion-plans-advance)
9. [Oklo, quarterly figures from its SEC filings, retrieved 13 October 2026](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001849056)


---

Oklo's cancer-isotope plant lands with no buyer, no price and a $6.5 billion bill — The Inference. Canonical: https://theinference.org/article/oklo-s-cancer-isotope-plant-lands-with-no-buyer-no-price-and-a-6-5-billion-bill